10 October 2019
ADVANCED ONCOTHERAPY PLC
("Advanced Oncotherapy" or the "Company")
Change of Broker
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that with effect from today Allenby Capital Limited will be the Company's Nominated Adviser and sole Broker.
Advanced Oncotherapy Plc
Dr. Michael Sinclair, Executive Chairman
Nicolas Serandour, CEO
Tel: +44 (0)20 3617 8728
Allenby Capital Limited (Nominated Adviser & Broker)
Nick Athanas / Liz Kirchner / Nicholas Chambers
Tel: +44 (0)20 3328 5656
FTI Consulting (Financial PR & IR)
Simon Conway / Rob Winder
Tel: +44 (0)20 3727 1000 [email protected]
About Advanced Oncotherapy Plc www.avoplc.com
Advanced Oncotherapy is a provider of particle therapy in the treatment of cancer, which harnesses the very best in modern technology. Advanced Oncotherapy's R&D team, ADAM, in Geneva, focuses on the development of a proprietary proton accelerator - LIGHT (Linac Image Guided Hadron Technology). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a compact and truly modular unit, offering significant cost advantages. LIGHT also delivers proton beams in a way that facilitates greater precision and electronic control, which are not achievable with currently available alternative technologies.
Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology, offering better health outcomes and lower treatment related side effects.
Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton or particle therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of cutting edge, cost-effective systems for particle therapy.